Rlay stock forecast the stock’s beta of 1

The stock’s beta of 1.12 suggests moderate correlation with market swings. If you would prefer to check out another company with better fundamentals, then do not miss this free list of interesting companies, that have HIGH return on equity and low debt or this list of stocks which are all forecast to grow . The upgrade of Relay Therapeutics to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term. The AI-driven data pipeline rollout in RLAY stock forecast is viewed positively, creating operational efficiencies projected to lift EBITDA margins by 2%. Analysts remain alert for news on strategic partnerships in the next quarter.